Selective serotonin re-uptake inhibitors in anorexia nervosa

Expert Opinion on Investigational Drugs

Volumn 13, Issue 4, 2004, Pages 349-357

  Vaswani, Meera ^a   Kalra, Harish ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anorexia nervosa; Pharmacotherapy; Selective serotonin re uptake inhibitors; Serotonin

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CYPROHEPTADINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORFLUOXETINE; PAROXETINE; PIMOZIDE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANOREXIA NERVOSA; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; EATING DISORDER; FAMILY THERAPY; HUMAN; MEDICAL LITERATURE; MORBIDITY; MORTALITY; NEUROBIOLOGY; PHENOMENOLOGY; PROGNOSIS; PSYCHOTHERAPY; RELAPSE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANIMALS; ANOREXIA NERVOSA; CLINICAL TRIALS; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 1842854562     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.4.349     Document Type: Review

References (68)

1. CARLSSON A: The discovery of the SSRIs: a milestone in neuropsychopharmacology and rational drug design. In: Selective Serotonin Reuptake Inbibitors (SSRIs). Past, Present and Future. Stanford SC (Ed). RG Landes Company, Texas, USA (1999):1-7.
2. STAHL SM: Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry. Psychopharmacol. Bull. (1992) 28:3-9.
3. PRESKORN SH: Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J. Clin. Psychiatry (1993) 54(Suppl.):14-34.
4. PRESKORN SH: Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int. Clin. Psychopharmacol. (1994) 9(Suppl. 3):13-19.
5. TORK I: Anatomy of the serotonergic system. Ann. NY Acad. Sci. (1990) 600:9-34.
6. FULLER RW, WONG DT, ROBERTSON DW et al.: A selective inhibitor of serotonin uptake. Med. Res. Rev. (1991) 11:17-34.
7. GOODWIN GM: How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J. Clin. Psychiatry, (1996) 57(Suppl. 4):9-13.
8. STAHL SM: Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. (1998) 51:215-235.
9. DAVIS LL, YONKERS KA, TRIVEDI M et al.: The mechanism of action of SSRIs: a new hypothesis. In: Selective Serotonin Reuptake Inhibitors (SSRIs): Past, Present and Future. Stanford SC (Ed). RG Landes Company, Texas, USA (1999):181-182.
10. BROSEN K: Drug-metabolizing enzymes and therapeutic drug monitoring in Psychiatry. Ther. Drug. Monit. (1996) 18:393-396.
11. BAUMANN P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. (1996) 31:444-469.
12. STANFORD SC: Prozac: panacea or puzzle? Trends. Pharmacol. Sci. (1996) 17:150-174.
13. DE JONGHE F, SWINKELS J: Selective serotonin reuptake inhibitors: Relevance of differences in their pharmacological and clinical profiles. CNS Drugs (1997) 7:452-467.
14. SPINA E, AVANOZO A, FACCIOLA G et al.: Effect of fluoxetine on plasma concentraion of clozapine and its major metabolites in patients with schizophrenia. Int. Clin. Psychopharmacol. (1998) 13:141-145.
15. HEMERYCK A, BELPAIRE FM: Selective serotonin reuptake inhibitors and cytochrome P450 mediated drug-drug interactions: an update. Curr. Drug Metab. (2002) 3(1):13-37.
16. GREENBLATT DJ, VON MOLTKE LL, SCHMIDER J et al.: Inhibition of human cytochrome P450-3A. Isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J. Clin. Pharmacol. (1996) 36:792-798.
17. POLLOCK BG: Citalopram: A comprehensive review. Expert. Opin. Pharmacother. (2000) 2(4):681-698.
18. BAUMANN P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int. Clin. Psychopharmacol. (1996) 11(Suppl. 1):5-11.
19. OWENS MJ, MORGAN WN, PLOTT SJ et al.: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. (1997) 283:1305-1322.
20. BAUMAN P, LARSEN F: The pharmacokinetics of citalopram. Rev. Contemp. Pharmacother. (1995) 6:287-295.
21. RICHELSON E: Pharmacology of antidepressants characteristics of the ideal antidepressant. Drug. Mayo. Clin. Proc. (1994) 69:1069-1081.
22. MURDOCH D, McTAVISH D: Sertraline. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive compulsive disorder. Drugs (1992) 44:604-624.
23. VAN HARTEN J: Overview of the pharmacokinetics of fluvoxamine. Clin. Pharmacokinet. (1995) 29(Suppl. 1):1-9.
24. KAYE CM, HADDOCK RE, LANGLEY PF et al.: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta. Psychiatr. Scand. (1989) 80(Suppl. 350):60-75.
25. VAN HARTEN J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. (1993) 24(3):203-220.
26. DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter Study. J. Affect. Disord. (1990) 18:289-299.
27. KUHS H, SCHLAKE HP, ROLF LH et al.: Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta. Psychiatr. Scand. (1992) 85(5):364-369.
28. JEPPESEN U, GRAM LF, VISTISEN K et al.: Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. (1996) 51:73-78.
29. SOVEL SV: What's new in the treatment of anorexia nervosa and bulimia? Medscape Womens Health (1996) 1:5.
30. TAKIMOTO Y, INUI A, KUMANO H et al.: Orexigenic/anorexigenic signals in bulimia nervosa. Curr. Mol. Med. (2003) 3:349-360.
31. HALMI KA. Anorexia Nervosa and Bulimia Nervosa. In: Child and Adolesc. Psychiatry: A comprehensive Text Book, 3rd edn. Melwin Lewis (Ed), Lippincott Williams and Wilikins, Philadelphia, USA (2002):692-700.
32. HOEK HW: Review of the epidemiological studies of eating disorders. Int. Rev. Psychiatry (1993) 5:61-74.
33. GOWERS S, MCMAHON JB: Social class and prognosis in anorexia nervosa. Int. J. Eat. Disord. (1989) 8:105-110.
34. HOEK HW: The incidence and prevalence of anorexia nervosa and bulimia nervosa in primary care. Psychol. Med. (1991) 21:455-460.
35. ECKERT E, HALMI KA, MARCHI P et al.: Comparison of bulimic and non-bulimic anorexia nervosa patients during treatment. Psychol. Med. (1987) 17:891-898.
36. HALMI KA, FALK JR: Anorexia nervosa: a study of outcome discriminators in exclusive dieters and bulimics. J Am Acad Child Psychiatry (1982) 21:4-7.
37. STROBER M, SALKIN B, BURROUGHS J: Validity of the bulimia-restrictor distinctions in anorexia nervosa: Parental personality characteristics and familial psychiatry morbidity. J. Nerv. Ment. Dis. (1982) 170:345-351.
38. [NO AUTHORS LISTED]: Diagnostic and statistical manual of mental disorders, 4th ed.test revision (DSM-IV-TR) Washington, DC: American Psychiatric Press. (2000) 583:586.
39. DEMITRACK MA, LESEM MD, LISTWACK SJ et al.: CSF oxytocin in anorexia nervosa and bulimia nervosa: clinical and pathophysiologic considerations. Am. J. Psychiatry (1990) 147:882-886.
40. HADIGN CM, WALSH TB, BUTTINGER C et al.: Behavioural and neuroendocrine response to meta-CPP in anorexia nervosa. Biol. Psychiatry (1995) 37:504-511
41. FRANK GK, KAYE WH, WELTZIN TE et al.: Altered response to metachlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration. Int. J. Eat. Disord. (2001) 30:57-68.
42. KAYE W, GENDALL K, STROBER M et al.: Serotonin neuronal functions and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol. Psychiatry (1998) 44:825-838
43. FAVA M, COPELAND PM, SCHWEIGER U et al.: Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Am. J. Psychiatry (1989) 146:963-971.
44. SHARMA A: Anorexia nervosa and bulimia nervosa: an appraisal. Drugs Today (Barc). (2001) 37:229-236.
45. KAYE WH, BERRETTINI W, GWIRTSMAN HE et al.: Altered cerebral spinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulemia nervosa. Arch. Gen. Psychiatry (1990) 47:548-556.
46. HALMI KA, ECKERT E, MARCHI P et al.: Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch. Gen. Psychiatry (1991) 48:712-718.
47. THEANDER S: Outcome and prognosis in anorexia nervosa and bulimia. In: Anorexia nervosa and bulimic disorders. Szmukler GI et al. (Eds), Pergamon, London, UK (1985):493-508.
48. BEN-TOVIN D, WALKER K, GILCHRIST P: Outcome in patients with eating disorders: a 5 year study. Lancet (2001) 357:1254-1257.
49. RUSSELL GFM: Anorexia and Bulimia Nervosa. In: Child and Adolescent Psychiatry, 2nd edn. Rutter M, Hersov L (Eds), Blackwell scientific publication, Oxford, UK (1985):625-637
50. HALMI KA: Eating disorders (anorexia nervosa, bulimia nervosa and obesity). In: Textbook of Clinical Psychiatry. Hales RE, Yudofsky SG (Eds), Am. Psychiatric Publishing, Washington DC, USA (2003) 1:1001-1021.
51. GARNER DM, ROCKERT W, OLMSTED MP et al.: Psycho educational principles in the treatment of bulimia and anorexia nervosa. In: Handbook of psychotherapy for anorexia nervosa and bulimia. Garner DM, Garfinkel PE (Eds), Guilford Press, New York, USA (1985):513-572.
52. APA practice guidelines for the treatment of patients with eating disorders (revision). Am. J. Psychiatry (2000) 157:39.
53. FERGUSON CP, LA VIA MC, CROSSAN PJ et al.: Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int. J. Eat. Disord. (1999) 25:11-17.
54. BARBARICH NC, MCCONAHA CW, HALMI KA et al.: Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int. J. Eat. Disord. (2004) 35(1):10-5.
55. MAYER LE, WALSH BT: The use of selective serotonin reuptake inhibitors in eating disorders, J. Clin. Psychiatry. (1998) Suppl. 15:28-34.
56. KIM SS: Role of fluoxetine in anorexia nervosa. Ann. Pharmacother. (2003) 37:890-892.
57. FERGUSON JM: Treatment of an anorexia nervosa patient with fluoxetine (letter) Am. J. Psychiatry (1987) 144:1239.
58. GWIRTSMAN HE, GUZE BH, YAGER J et al.: Fluoxetine treatment of anorexia nervosa: an open clinical trial. J. Clin. Psychiatry (1990) 51:378-382.
59. KAYE WH, WELTZIN TE, HSU LK et al.: An open trial of fluoxetine in patients with anorexia nervosa. J. Clin. Psychiatry (1991) 52:464-471.
60. ATTIA E, HAIMAN C, WALSH T et al.: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am. J. Psychiatry (1998) 155:548-551.
61. STROBER M, FREEMAN R, DE ANTONIO M et al.: Does fluoxetine influence the post-hospital course of restrictor type anorexia nervosa? A 24 month prospective, longitudinal follow up and comparison and historical controls. Psychopharmacol Bull. (1997) 33:425-431.
62. KAYE WH, NAGATA T, WELTZIN TE et al.: Double-blind placebo controlled administration of fluoxetine in restricting and restricting-purging type anorexia nervosa. Biol. Psychiatry (2001) 49:644-652.
63. HEIDEN A, ZWAAN M, FREY R et al.: Paroxetine in a patient with obsessive-cumpulsive disorder, anorexia nervosa and schizotypal personality disorder. J. Psychiatry Neurosci. (1998) 23:179-180.
64. SANTONASTASO P, FRIEDERICI S, FAVARO A: Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J. Child Adolsc. Psychopharmacol. (2001) 11:143-150.
65. FRANK GK, KAYE WH, MARCUS MD: Sertraline in underweight binge eating/purging-type eating disorders: five case reports. Int. J. Eat. Disord. (2001) 29(4):495-498.
66. FASSINO S, LEOMBRUNI P, DAGA GA et al.: Efficacy of citalopram in anorexia nervosa: a pilot study. Eur. Neuropsychopharmacol. (2002) 12:453-459.
67. BERGH C, ERIKSSON M, LINDBERG G et al.: Selective serotonin reuptake inhibitors in anorexia (letter). Lancet (1996) 348:1459-1460.
68. MITCHELL JE, TAREEN B, SHEEHAN W et al.: Establishing guidelines for pharmacotherapy trials in bulimia nervosa and anorexia nervosa. Int. J. Eat. Disord, (2000) 28:1-7.